Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

18.2%

2 terminated/withdrawn out of 11 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
8(72.7%)
Early Phase 1
3(27.3%)
11Total
Phase 1(8)
Early Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT07487597Early Phase 1Recruiting

Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors

Role: lead

NCT07108140Early Phase 1Terminated

Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors

Role: lead

NCT03578406Phase 1Completed

HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer

Role: collaborator

NCT05357027Phase 1Terminated

HPV16 E6 TCR T Cells for Cervical Carcinoma

Role: lead

NCT04139057Phase 1Completed

EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC

Role: collaborator

NCT04627740Phase 1Completed

Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors

Role: collaborator

NCT06355908Phase 1Suspended

IL13Rα2 CAR-T for Patients With r/r Glioma

Role: collaborator

NCT04509726Phase 1Completed

EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma

Role: collaborator

NCT07246304Early Phase 1Recruiting

TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC

Role: lead

NCT05881525Phase 1Recruiting

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Role: lead

NCT04749641Phase 1Completed

Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma

Role: collaborator

All 11 trials loaded